Norgine's CEO Janneke van der Kamp has said other portfolio-boosting deals could be on the way. Netherlands-based pharma group Norgine has expanded its rare disease portfolio with the acquisition ...

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines ...

Theravia was formed through the merger of Addmedica and CTRS Theravia has recorded over €50 million in annual revenues Norgine is a pharmaceutical and consumer healthcare company Mérieux Equity ...

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines ...